Reviva Pharmaceuticals Prices Highly Dilutive $10M Public Offering with Warrants Amidst Delisting Risk
RVPH sits 27% above its 52-week low of $0.67 on elevated volume (23× avg).
Summary
Reviva Pharmaceuticals priced a $10.0 million public offering of common stock and warrants at a deep discount, leading to extreme dilution for existing shareholders as the company battles a going concern warning and Nasdaq delisting threat.
Key Events · Financing and Capital Events · RVPH
-
Public Offering Priced
The company priced a public offering of 6,283,334 shares of common stock and 383,333 pre-funded warrants, along with Series G and Series H common warrants to purchase up to 6,666,667 shares each. The combined public offering price for each unit (common stock or pre-funded warrant plus two accompanying warrants) is $1.50, raising approximately $10.0 million in gross proceeds.
-
Significant Dilution
The offering represents a substantial capital raise relative to the company's market capitalization. The 6,666,667 common stock equivalents offered (common stock + pre-funded warrants) represent over 100% of the 6,443,710 shares outstanding as of March 17, 2026. If all warrants are exercised, the potential dilution to existing shareholders could exceed 300%.
-
Deep Discount Pricing
The offering price of $1.50 per unit is a significant discount compared to the last reported sales price of $1.87 per share on March 18, 2026, the date of the prospectus supplement. This indicates the company had to offer very favorable terms to attract investors.
-
Critical Capital for Distressed Company
This capital raise is crucial for Reviva Pharmaceuticals, which has disclosed a 'going concern' warning and faces a Nasdaq delisting deadline of March 27, 2026, due to its failure to maintain a minimum bid price of $1.00, despite a recent 1-for-20 reverse stock split. The proceeds are earmarked for research and development, including a planned Phase 3 trial for its lead drug candidate, brilaroxazine.
Analysis · RVPH · Life Sciences
Reviva Pharmaceuticals has priced a public offering to raise approximately $10.0 million in gross proceeds, selling common stock and multiple series of warrants at a combined price of $1.50 per unit. This offering is highly dilutive, representing roughly 93% of the company's current market capitalization and potentially increasing outstanding shares by over 100% immediately, with further significant dilution possible from warrant exercises. The offering price of $1.50 was set at a substantial discount to the last reported sales price of $1.87 on March 18, 2026, the date of the prospectus supplement. This capital raise is critical for the company, which has a going concern warning and faces a Nasdaq delisting deadline of March 27, 2026, for failing to meet the minimum bid price requirement, despite a recent 1-for-20 reverse stock split. The proceeds are intended to fund research and development, including a planned Phase 3 trial for brilaroxazine in schizophrenia, and for general corporate purposes. While securing capital is a lifeline, the extremely dilutive terms and the company's precarious financial position signal significant challenges for existing shareholders.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RVPH was trading at $0.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.8M. The 52-week trading range was $0.67 to $23.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.